Library
Daiichi Sankyo's New CEO Charts Next Chapter After ADC Success
Daiichi Sankyo's antibody-drug conjugates, including Enhertu and Datroway, have made it a leader in oncology and secured major licensing deals with AstraZeneca and Merck. New CEO Hiroyuki Okuzawa plans to leverage these five ADCs to treat over 30 tumor types by 2030 but must also identify the next growth driver beyond ADCs. The company faces execution risks with partnered programs and a declining stock price.
Revolution Medicines' Daraxonrasib Shows 'Unprecedented' Survival Benefit in Pancreatic Cancer
Revolution Medicines' daraxonrasib demonstrated a median overall survival of 13.2 months in a Phase 3 trial of patients with metastatic pancreatic cancer, nearly double the 6.6 months seen with chemotherapy in those with RAS G12 mutations. The data, presented at the American Society of Clinical Oncology meeting, were called 'unprecedented' and 'landscape-changing' by experts. The FDA approved the drug, sold as Rasonque, in late August. Daraxonrasib also extended progression-free survival to 7.3 months in RAS G12 patients versus 3.5 months for chemotherapy. The drug's novel mechanism, binding to KRAS in its active state, has propelled Revolution into the upper echelon of biotechnology, with analysts estimating a potential $10 billion market opportunity in pancreatic cancer alone.
Radiopharmaceuticals for Cancer: Precision Radiation Delivery Advances
Radiopharmaceuticals are drugs that precisely deliver radioactive material to tumors, offering a targeted punch of radiation. Novartis's Pluvicto, approved in 2022 for prostate cancer, validated the field, but manufacturing and distribution challenges persist. Despite early setbacks, technical advancements and big pharma investments have spurred a wave of startups and renewed interest, with companies like Bayer and Fusion Pharmaceuticals advancing new candidates. This article provides a snapshot of the field's evolution and key players.
FDA Unveils New Roadmap for Testing Personalized Therapies
The FDA has issued long-awaited draft guidance aimed at accelerating the development of personalized therapies for extremely rare diseases. The guidance details a 'plausible mechanism pathway' that allows approval based on a single well-controlled clinical investigation plus confirmatory evidence, rather than randomized controlled trials, which are often infeasible for ultra-rare conditions. The move follows the case of KJ Muldoon, a baby who received a custom CRISPR-based gene-editing treatment at Children's Hospital of Philadelphia. HHS Secretary Robert F. Kennedy Jr. and FDA leaders highlighted the framework's potential to transform drug development for rare diseases, with expectations of a surge in applications.
Biotech's Rebound Faces a Stress Test at J.P. Morgan
The biotech sector is showing signs of recovery from a historic downturn, with increased dealmaking and venture funding. At the J.P. Morgan Healthcare Conference, attendees expressed renewed optimism, but also caution that the rebound may not last. Factors such as China's rising biotech ecosystem, FDA unpredictability, and the potential for another bubble were discussed. Experts emphasized the need for discipline to avoid repeating past mistakes.
Biotech’s Commercial Evolution: More Drugmakers Bet on Themselves
Biotech investors have historically bet on M&A, but a growing number of young drugmakers are trying to commercialize their own medicines—and succeeding. BridgeBio, Argenx, Insmed, and Madrigal have all beaten sales expectations, rewarding shareholders who stuck around. Companies like Alumis and LB Pharmaceuticals are weighing whether to launch their own drugs, while Kailera intends to do so. Analysts say this trend reflects a maturing sector, with more companies achieving self-sustaining businesses.
The Progress Profile: Alzheimer’s Research in Focus Returns for Season 2
The Progress Profile: Alzheimer’s Research in Focus podcast returns for Season 2, featuring four episodes that delve into critical conversations about Alzheimer’s and brain health. Episodes cover bridging science and lived experience, policy and equity in dementia care, advocacy and awareness across neurodegenerative diseases, and patient perspectives on risk and prevention. Experts including Dr. John Harrison, Dr. Lon Schneider, Dr. Stephen Salloway, Dr. Phyllis Ferrell, Maria Carrillo, Ph.D., and Dr. Wiesje van der Flier discuss advances in early detection, blood-based diagnostics, emerging therapies, and the importance of patient and caregiver perspectives in shaping research and care.
The Progress Profile: Alzheimer’s Research in Focus Podcast Returns for Season 2
The Progress Profile: Alzheimer’s Research in Focus podcast is back for Season 2, building on Season 1 to delve deeper into neurodegenerative disease. The season features four episodes: Ep. 1 discusses bridging clinical trial design and frontline care with Dr. John Harrison, Dr. Lon Schneider, and Dr. Stephen Salloway; Ep. 2 explores policy, equity, and the expanding dementia landscape with Dr. Phyllis Ferrell; Ep. 3 covers awareness and advocacy across neurodegenerative diseases with Maria Carrillo, Ph.D.; and Ep. 4 examines patient perspectives on risk, prevention, and empowerment with Dr. Wiesje van der Flier. The podcast is filed under Pharma, Clinical Trials, and Marketing.
BioPharma Dive Trendline on Commercialization
Young biotech companies are usually acquired rather than growing into profitable enterprises, but recently more and more companies have tried independent commercialization and succeeded.
BioPharma Dive Trendline on Alzheimer's disease
Detailed data from Biogen's mid-stage 'Celia' trial show that its tau-targeting drug BIIB080 slowed the decline in CDR-SB scores by 26% in the lowest-dose group over 18 months, comparable to the efficacy of approved amyloid drugs. However, the trial was a technical failure because the dose-response relationship did not meet expectations, yet the company still plans to advance to Phase III. Analysts are divided on the drug's commercial prospects and strategic value.